Dapagliflozin Reduces MACE, CV Death in Patients With T2D and Prior MI
Dapagliflozin reduces MACE, CV death, and risk for heart failure hospitalization in patients with type 2 diabetes and prior MI.
Myocardial Infarction
Preventing Cardiovascular Comorbidities in Adults Aging With HIV
Interventions to reduce some traditional risk factors can improve the proportion of non-AIDS-related comorbidities.
Medication Education Program Leads to ACS Hospital Readmission Reductions
A patient’s understanding of and compliance with their medication treatment regimens post-myocardial infarction is key to reducing 30-day hospital readmission rates.
Endogenous Testosterone Linked to Cardiovascular Disease
Genetically predicted endogenous testosterone may have role in thromboembolism, heart failure, MI.
Incidence of Acute Myocardial Infarction Increased Among Young Women
The incidence of acute myocardial infarctions has increased in younger women, and sedentary time is associated with an increased risk for cardiovascular disease in women.
Prevalence of Modifiable CV Risk Factors High in Young Adults With First AMI
The most prevalent risk factors in patients between the ages of 18 and 44 years with a first acute myocardial infarction were smoking, dyslipidemia, and hypertension.
Nurse Navigators Improve Outcomes Following ACS Hospitalization
Nurse navigators can improve care coordination and outcomes following hospitalization for an acute myocardial infarction.
CDC: Heart Attack Awareness Improved Since 2008
Since 2008, there has been an increase in the number of US adults with awareness of heart attack symptoms and knowledge of the appropriate response to a heart attack.
Infection and Infarction: Cause and Effect?
Investigators sought to confirm long-standing hypotheses that acute infections can lead to myocardial infarction.
Co-Payment Vouchers Increase P2Y12 Inhibitor Persistence in Patients With MI
Researchers examined the effect of a co-payment voucher to offset medication payment costs on continual P2Y12 inhibitor use and on risk for major adverse cardiovascular events at 1 year in adult patients with myocardial infarction discharged with prescriptions for clopidogrel or ticagrelor.
